Table 1 Baseline characteristics
Characteristics | Number of patients, % (n = 8) |
|---|---|
Age (years) | |
˂60 | 1 (12.5%) |
≥60 | 7 (87.5%) |
Sex | |
Male | 5 (62.5%) |
Female | 3 (37.5%) |
History | |
DLBCL-GCB | 1 (12.5%) |
DLBCL-non-GCB | 5 (62.5%) |
MCL | 1 (12.5%) |
tFL | 1 (12.5%) |
Disease stage at study entry | |
I or II | 3 (37.5%) |
III or IV | 5 (62.5%) |
ECOG score | |
0 | 1(12.5%) |
1 | 7 (87.5%) |
IPI score | |
0–1 | 1 (12.5%) |
2–3 | 5 (62.5%) |
4–5 | 2 (25%) |
LDH | |
<240 | 3 (37.5%) |
≥240 | 5 (62.5%) |
Extra nodal organ involvement | |
0 | 1 (12.5%) |
<2 | 2 (25%) |
≥2 | 5 (62.5%) |
Number of previous lines of antineoplastic therapy | |
3 | 2 (25%) |
4–8 | 6 (75%) |
Refractory or relapse | |
Primary refractory | 6 (75%) |
Relapse | 2 (25%) |
Prior CD19 CAR T-cell therapy | |
CAR-T | 3 (37.5%) |
None | 5 (62.5%) |
